Skip to main content
. 2017 Apr 30;96(7):1113–1120. doi: 10.1007/s00277-017-2994-x

Fig. 3.

Fig. 3

JAK2 p.V617F allele burden before and after crossover in patients initially treated with IFN as BAT (n = 13). a Percentage change in JAK2 p.V617F allele burden over time for individual patients. b Mean maximal percentage change in JAK2 p.V617F allele burden before versus after crossover. BAT best available therapy, IFN interferon